With the association of specific neoantigens (NY-ESO-1 and MAGE-A4) and the absence of immunosuppressive microenvironment, the future of immunotherapy in synovial sarcoma probably lies in the targeting of specific neoantigens. This evidence concerns the gene MAGEA4 and synovial sarcoma.